🎯 Drug Targets

Browse 10 drug targets with druggability analysis, composite scores, and clinical context

10
Targets
0
High Druggability
0.60
Avg Score
15
Target Classes
Druggability Distribution
High: 0Medium: 3Low: 7Unknown: 0
Avg druggability score: 0.405
Clinical Pipeline
Approved: 5Phase III: 1Phase II: 3Phase I: 1Preclinical: 0
Total compounds: 18 · Approved: 6
Filtered by: class=ligand — 10 results
IL1B Interleukin-1 beta Phase 4
Ligand Medium Druggability
Score
0.73
Drug.
0.49
Safety
0.60
Drugs
2
Hyps
3
Papers
0
IL-1 receptor antagonist or neutralizing monoclonal antibody
APOE Apolipoprotein E Phase 2
Ligand Medium Druggability
Score
0.64
Drug.
0.47
Safety
0.40
Drugs
4
Hyps
50
Papers
31
Protein-protein interaction modulator or lipid metabolism enhancer
ANGPT1 Angiopoietin-1 Phase 4
Ligand Low Druggability
Score
0.63
Drug.
0.45
Safety
0.50
Drugs
1
Hyps
1
Papers
18
Protein therapeutics or small molecule mimetics activating Tie2 signaling
TGFB1 Transforming growth factor beta-1 Phase 3
Ligand Low Druggability
Score
0.63
Drug.
0.44
Safety
0.30
Drugs
2
Hyps
3
Papers
18
Monoclonal antibodies neutralizing TGF-β1 or small molecule inhibitors of TGF-β signaling
IL10 Interleukin-10 Phase 2
Ligand Low Druggability
Score
0.62
Drug.
0.36
Safety
0.30
Drugs
1
Hyps
3
Papers
0
Recombinant protein replacement or monoclonal antibody modulation
BDNF Brain Derived Neurotrophic Factor Phase 2
Ligand Low Druggability
Score
0.59
Drug.
0.29
Safety
0.60
Drugs
1
Hyps
47
Papers
18
Protein replacement therapy or small molecule mimetic
NTN1 Netrin-1 Phase 1
Ligand Low Druggability
Score
0.57
Drug.
0.36
Safety
0.50
Drugs
1
Hyps
1
Papers
24
Modulation of axon guidance and neuronal survival pathways
HCRT Hypocretin/Orexin Phase 4
Ligand Medium Druggability
Score
0.55
Drug.
0.46
Safety
0.60
Drugs
3
Hyps
3
Papers
31
Peptide hormone replacement or stabilization approaches
SST Somatostatin Phase 4
Ligand Low Druggability
Score
0.54
Drug.
0.41
Safety
0.70
Drugs
2
Hyps
5
Papers
0
Somatostatin is a peptide neurotransmitter that modulates neuronal signaling by inhibiting hormone release and neuronal excitability, with emerging evidence suggesting its potential neuroprotective role in neurodegenerative processes through regulation of inflammatory responses and synaptic plasticity. In neurodegeneration contexts, SST receptors may serve as modulators of neuroinflammatory cascades and potentially mitigate progressive neuronal damage through receptor-mediated signaling mechanisms.
CRH Corticotropin Releasing Hormone Phase 4
Ligand Low Druggability
Score
0.54
Drug.
0.34
Safety
0.60
Drugs
1
Hyps
1
Papers
18
CRH receptor antagonist blocking stress hormone signaling